Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
तुलना करने के लिए मीट्रिक्स | PHAR | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधPHARपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 3,683.9x | 9.3x | −0.6x | |
PEG अनुपात | 36.40 | 0.01 | 0.00 | |
क़ीमत/बुक | 5.3x | 1.6x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 3.9x | 2.9x | 3.4x | |
अपसाइड (विश्लेषक लक्ष्य) | 30.0% | 36.4% | 44.4% | |
उचित मूल्य अपसाइड | अनलॉक करें | 5.5% | 6.1% | अनलॉक करें |